Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Schizophrenia
Brief Summary: The purpose of the this trial is to evaluate the efficacy, safety, and tolerability of an intramuscular (IM) depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia

The trial is designed into three treatment phases. Phase 1 is designed to allow for a subject to be converted from the current anti-psychotic treatment to oral non-generic aripiprazole monotherapy (oral conversion phase from 4 to 6 weeks). During Phase 2 the subject will be stabilized on oral non-generic aripiprazole monotherapy. Once the subject is stabilized in Phase 2 (oral stabilization phase from minimum 8 weeks to maximum 28 weeks), they are eligible to be randomized into the double-blind IM depot maintenance phase, Phase 3. During Phase 3, the subject will be assessed for exacerbation of psychotic symptoms and impending relapse for up to 38 weeks.


Options:
A: Arm Label: Bifeprunox; Type: EXPERIMENTAL; Interventions: Drug: Bifeprunox | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Quetiapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine | Intervention Type: DRUG; Name: Bifeprunox; Assigned to Arm(s): Bifeprunox | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Quetiapine
B: Arm Label: Aripiprazole depot 300 or 400 mg; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot 300 or 400 mg, Drug: Placebo tablets | Arm Label: Aripiprazole 10-30 mg orally; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole 10-30 mg orally, Drug: Placebo depot | Arm Label: Aripiprazole depot 25 or 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot 25 or 50 mg, Drug: Placebo tablets | Intervention Type: DRUG; Name: Aripiprazole depot 300 or 400 mg; Assigned to Arm(s): Aripiprazole depot 300 or 400 mg | Intervention Type: DRUG; Name: Aripiprazole 10-30 mg orally; Assigned to Arm(s): Aripiprazole 10-30 mg orally | Intervention Type: DRUG; Name: Aripiprazole depot 25 or 50 mg; Assigned to Arm(s): Aripiprazole depot 25 or 50 mg | Intervention Type: DRUG; Name: Placebo depot; Assigned to Arm(s): Aripiprazole 10-30 mg orally | Intervention Type: DRUG; Name: Placebo tablets; Assigned to Arm(s): Aripiprazole depot 25 or 50 mg, Aripiprazole depot 300 or 400 mg
C: Arm Label: Aripiprazole depot; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot | Arm Label: Placebo depot; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo depot | Intervention Type: DRUG; Name: Aripiprazole depot; Assigned to Arm(s): Aripiprazole depot | Intervention Type: DRUG; Name: Placebo depot; Assigned to Arm(s): Placebo depot
D: Arm Label: Bifeprunox; Type: EXPERIMENTAL; Interventions: Drug: Bifeprunox | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Quetiapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine | Intervention Type: DRUG; Name: Bifeprunox; Assigned to Arm(s): Bifeprunox | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Quetiapine

Answer: B